- Home
- INKT vs RNXT Comparison
INKT vs RNXT Comparison
Compare INKT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- RNXT
- Stock Information
- Founded
- INKT 2017
- RNXT 2012
- Country
- INKT United States
- RNXT United States
- Employees
- INKT N/A
- RNXT N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- RNXT Health Care
- Exchange
- INKT Nasdaq
- RNXT Nasdaq
- Market Cap
- INKT 69.2M
- RNXT 44.6M
- IPO Year
- INKT 2021
- RNXT 2021
- Fundamental
- Price
- INKT $14.40
- RNXT $1.28
- Analyst Decision
- INKT Buy
- RNXT Strong Buy
- Analyst Count
- INKT 3
- RNXT 2
- Target Price
- INKT $37.50
- RNXT $7.50
- AVG Volume (30 Days)
- INKT 56.4K
- RNXT 594.5K
- Earning Date
- INKT 11-13-2025
- RNXT 11-12-2025
- Dividend Yield
- INKT N/A
- RNXT N/A
- EPS Growth
- INKT N/A
- RNXT N/A
- EPS
- INKT N/A
- RNXT N/A
- Revenue
- INKT N/A
- RNXT $662,000.00
- Revenue This Year
- INKT N/A
- RNXT $2,988.37
- Revenue Next Year
- INKT N/A
- RNXT $300.60
- P/E Ratio
- INKT N/A
- RNXT N/A
- Revenue Growth
- INKT N/A
- RNXT N/A
- 52 Week Low
- INKT $4.56
- RNXT $0.75
- 52 Week High
- INKT $76.00
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- INKT 47.71
- RNXT 61.50
- Support Level
- INKT $13.11
- RNXT $1.06
- Resistance Level
- INKT $16.20
- RNXT $1.27
- Average True Range (ATR)
- INKT 1.21
- RNXT 0.10
- MACD
- INKT 0.05
- RNXT 0.04
- Stochastic Oscillator
- INKT 40.40
- RNXT 69.64
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.